Pharmacological Management of Treatment-Resistant Pediatric Depression
Saved in:
| Title: | Pharmacological Management of Treatment-Resistant Pediatric Depression |
|---|---|
| Language: | English |
| Authors: | Kratochvil, Christopher J., Wagner, Karen Dineen, Emslie, Graham |
| Source: | Journal of the American Academy of Child and Adolescent Psychiatry. Feb 2005 44(2):198-198. |
| Availability: | Lippincott Williams & Wilkins, P.O. Box 1620, Hagerstown, MD 21741. Tel: 800-638-3030 (Toll Free); Fax: 301-223-2400. |
| Peer Reviewed: | Y |
| Page Count: | 3 |
| Publication Date: | 2005 |
| Document Type: | Journal Articles Opinion Papers |
| Education Level: | Higher Education |
| Descriptors: | Early Adolescents, Depression (Psychology), Drug Therapy, Psychopathology, Behavior Modification, Cognitive Restructuring, Psychotherapy, Clinical Diagnosis |
| ISSN: | 0890-8567 |
| Abstract: | A 13-year-old boy presents with treatment-resistant symptoms of major depression. This is his first episode of depression, initially treated with 200 mg sertraline for 12 weeks with no significant benefit. The severe depression has shown a partial response to weekly cognitive-behavioral therapy (CBT) and fluoxetine, which was titrated up to 60 mg daily 12 weeks ago. Suicidal ideation and insomnia are gone, energy is elevated to an appropriate level, appetite is normalized, and social and academic functioning are improved. Unfortunately, his dysphoria, anhedonia, guilt, and poor concentration remain problematic. There is a family history of major depression in his father and bipolar disorder in a paternal aunt. When asked how they would address this patient's case pharmacologically, three of the authors share their professional insight, and experience as they thoughtfully consider the pertinent issues in this case such as symptom presentation, assessment procedures, correctness of diagnosis, comorbid conditions, medication compliance, possibility of latent substance abuse, family pathology, and minimizing chances of drug-drug interaction and side affects as they each weigh the clinical evidence, review the patient's history, reach a conclusion, and develop the most reasonable psychopharmacological treatment strategy for this patient. |
| Abstractor: | ERIC |
| Number of References: | 13 |
| Entry Date: | 2005 |
| Accession Number: | EJ710981 |
| Database: | ERIC |
| Abstract: | A 13-year-old boy presents with treatment-resistant symptoms of major depression. This is his first episode of depression, initially treated with 200 mg sertraline for 12 weeks with no significant benefit. The severe depression has shown a partial response to weekly cognitive-behavioral therapy (CBT) and fluoxetine, which was titrated up to 60 mg daily 12 weeks ago. Suicidal ideation and insomnia are gone, energy is elevated to an appropriate level, appetite is normalized, and social and academic functioning are improved. Unfortunately, his dysphoria, anhedonia, guilt, and poor concentration remain problematic. There is a family history of major depression in his father and bipolar disorder in a paternal aunt. When asked how they would address this patient's case pharmacologically, three of the authors share their professional insight, and experience as they thoughtfully consider the pertinent issues in this case such as symptom presentation, assessment procedures, correctness of diagnosis, comorbid conditions, medication compliance, possibility of latent substance abuse, family pathology, and minimizing chances of drug-drug interaction and side affects as they each weigh the clinical evidence, review the patient's history, reach a conclusion, and develop the most reasonable psychopharmacological treatment strategy for this patient. |
|---|---|
| ISSN: | 0890-8567 |
